CZ20031277A3 - Postup přípravy latentního antitrombinu III postup přípravy - Google Patents
Postup přípravy latentního antitrombinu III postup přípravy Download PDFInfo
- Publication number
- CZ20031277A3 CZ20031277A3 CZ20031277A CZ20031277A CZ20031277A3 CZ 20031277 A3 CZ20031277 A3 CZ 20031277A3 CZ 20031277 A CZ20031277 A CZ 20031277A CZ 20031277 A CZ20031277 A CZ 20031277A CZ 20031277 A3 CZ20031277 A3 CZ 20031277A3
- Authority
- CZ
- Czechia
- Prior art keywords
- sample
- sulfate
- buffer
- hepes
- range
- Prior art date
Links
- 102000004411 Antithrombin III Human genes 0.000 title claims abstract description 61
- 108090000935 Antithrombin III Proteins 0.000 title claims abstract description 61
- 229960005348 antithrombin iii Drugs 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000000872 buffer Substances 0.000 claims abstract description 25
- 230000008569 process Effects 0.000 claims abstract description 15
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 13
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 47
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 38
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 34
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 34
- 239000007995 HEPES buffer Substances 0.000 claims description 29
- 230000002779 inactivation Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 229910052936 alkali metal sulfate Inorganic materials 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims 2
- 238000011534 incubation Methods 0.000 abstract description 13
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 47
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
- 229960002897 heparin Drugs 0.000 description 15
- 229920000669 heparin Polymers 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000004019 antithrombin Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 201000005657 Antithrombin III deficiency Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- YCAGGFXSFQFVQL-UHFFFAOYSA-N Endothion Chemical compound COC1=COC(CSP(=O)(OC)OC)=CC1=O YCAGGFXSFQFVQL-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NZWFHQBPGLLIDU-UHFFFAOYSA-N N[Ag]N Chemical compound N[Ag]N NZWFHQBPGLLIDU-UHFFFAOYSA-N 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000033666 hereditary antithrombin deficiency Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010850 salt effect Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004086A SE0004086D0 (sv) | 2000-11-08 | 2000-11-08 | Preparation process |
| US25214800P | 2000-11-20 | 2000-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20031277A3 true CZ20031277A3 (cs) | 2003-08-13 |
Family
ID=26655296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20031277A CZ20031277A3 (cs) | 2000-11-08 | 2001-11-08 | Postup přípravy latentního antitrombinu III postup přípravy |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1332159A1 (pl) |
| JP (1) | JP2004522707A (pl) |
| KR (1) | KR20030057545A (pl) |
| AU (1) | AU2002214468A1 (pl) |
| BR (1) | BR0115188A (pl) |
| CA (1) | CA2428055A1 (pl) |
| CZ (1) | CZ20031277A3 (pl) |
| EE (1) | EE200300218A (pl) |
| HU (1) | HUP0301766A3 (pl) |
| IL (1) | IL155539A0 (pl) |
| MX (1) | MXPA03004030A (pl) |
| NO (1) | NO20032048L (pl) |
| PL (1) | PL360410A1 (pl) |
| RU (1) | RU2003117016A (pl) |
| WO (1) | WO2002038610A1 (pl) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
| US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
| US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
| US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
| SE0203770D0 (sv) * | 2002-12-19 | 2002-12-19 | Biovitrum Ab | Method of separation |
| WO2006086200A1 (en) | 2005-02-07 | 2006-08-17 | Hanuman Llc | Plasma concentrator device |
| US7694828B2 (en) | 2005-04-27 | 2010-04-13 | Biomet Manufacturing Corp. | Method and apparatus for producing autologous clotting components |
| US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
| US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
| JP5479319B2 (ja) | 2007-04-12 | 2014-04-23 | バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー | ブイ式懸濁液分画システム |
| WO2009108890A1 (en) | 2008-02-27 | 2009-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| WO2009111338A1 (en) | 2008-02-29 | 2009-09-11 | Biomet Manufacturing Corp. | A system and process for separating a material |
| US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
| US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
| US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
| US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US9550028B2 (en) | 2014-05-06 | 2017-01-24 | Biomet Biologics, LLC. | Single step desiccating bead-in-syringe concentrating device |
-
2001
- 2001-11-08 RU RU2003117016/13A patent/RU2003117016A/ru not_active Application Discontinuation
- 2001-11-08 CZ CZ20031277A patent/CZ20031277A3/cs unknown
- 2001-11-08 WO PCT/SE2001/002473 patent/WO2002038610A1/en not_active Ceased
- 2001-11-08 EP EP01983012A patent/EP1332159A1/en not_active Withdrawn
- 2001-11-08 PL PL36041001A patent/PL360410A1/pl unknown
- 2001-11-08 JP JP2002541941A patent/JP2004522707A/ja active Pending
- 2001-11-08 KR KR10-2003-7005757A patent/KR20030057545A/ko not_active Ceased
- 2001-11-08 MX MXPA03004030A patent/MXPA03004030A/es unknown
- 2001-11-08 CA CA002428055A patent/CA2428055A1/en not_active Abandoned
- 2001-11-08 IL IL15553901A patent/IL155539A0/xx unknown
- 2001-11-08 AU AU2002214468A patent/AU2002214468A1/en not_active Abandoned
- 2001-11-08 EE EEP200300218A patent/EE200300218A/xx unknown
- 2001-11-08 BR BR0115188-6A patent/BR0115188A/pt not_active Application Discontinuation
- 2001-11-08 HU HU0301766A patent/HUP0301766A3/hu unknown
-
2003
- 2003-05-07 NO NO20032048A patent/NO20032048L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1332159A1 (en) | 2003-08-06 |
| IL155539A0 (en) | 2003-11-23 |
| MXPA03004030A (es) | 2004-02-12 |
| NO20032048D0 (no) | 2003-05-07 |
| JP2004522707A (ja) | 2004-07-29 |
| HUP0301766A3 (en) | 2005-12-28 |
| NO20032048L (no) | 2003-05-07 |
| PL360410A1 (pl) | 2004-09-06 |
| BR0115188A (pt) | 2004-02-03 |
| RU2003117016A (ru) | 2004-12-10 |
| KR20030057545A (ko) | 2003-07-04 |
| EE200300218A (et) | 2003-08-15 |
| CA2428055A1 (en) | 2002-05-16 |
| AU2002214468A1 (en) | 2002-05-21 |
| WO2002038610A1 (en) | 2002-05-16 |
| HUP0301766A2 (hu) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020090711A1 (en) | Process for preparing latent antithrombin III | |
| WO2002038610A1 (en) | Process for the preparation of latent antithrombin iii | |
| Olson et al. | Regulation of thrombin activity by antithrombin and heparin | |
| US6486306B1 (en) | Filtration | |
| US5777081A (en) | Process for producing an inter-alpha-trypsin inhibitor concentrate for therapeutic use and concentrate thus obtained | |
| JP2009524622A (ja) | 創傷治癒支援因子の精製および使用 | |
| JPH10509144A (ja) | ▲ｖｉｉｉ▼因子の精製方法 | |
| WO2002060925A1 (en) | Method of producing latent antithrombin iii | |
| US8076462B2 (en) | Method for producing antithrombin composition | |
| EP0652900B1 (en) | Thrombin inhibitors | |
| JP6096613B2 (ja) | 細胞培養由来のアルファ１プロテアーゼ阻害剤の精製 | |
| EP0282363B1 (fr) | Procédé d'obtention d'un concentré d'alpha 1-antitrypsine à partir d'une fraction de plasma humain et son utilisation à titre de médicament | |
| Karlsson et al. | Separation of latent, prelatent, and native forms of human antithrombin by heparin affinity high-performance liquid chromatography | |
| ZA200303492B (en) | Process for the preparation of latent antithrombin III. | |
| Karlsson | Pasteurization of antithrombin without generation of the prelatent form of antithrombin | |
| Karlsson et al. | Preparative conversion of native human antithrombin to the latent form | |
| AU777294B2 (en) | Process for the purification of antithrombin-III | |
| CA2395489A1 (en) | Process for the purification of antothrombin-iii | |
| CN119013036A (zh) | 制备白蛋白制剂的方法 | |
| AU682274C (en) | Filtration | |
| WO2004056870A2 (en) | Method for separation of antithrombin | |
| JP2022551566A (ja) | 第ＸＩａ因子のヘパリン非感受性アッセイ | |
| Becerra | A Noninhibitory Serpin with Neurotrophic Activity | |
| JPWO2000043412A1 (ja) | 高度に精製されたヘパリンコファクターｉｉ含有組成物およびその分離方法 | |
| WO2000043412A1 (en) | Compositions containing highly purified heparin cofactor ii and method for separating the same |